Investors Exercise Caution With Speculative Biotech Firms

Recent studies have shown that the chances of FDA approval for early stage drugs is dropping significantly, with medication designed to treat cancer being one of the least likely to receive regulatory authorization. Although it remains an exciting time …
See all stories on this topic »